Shares of Zosano Pharma Corp (NASDAQ:ZSAN) gapped up prior to trading on Friday . The stock had previously closed at $0.87, but opened at $0.95. Zosano Pharma shares last traded at $1.00, with a volume of 12,714,518 shares traded.
Several brokerages recently weighed in on ZSAN. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Zosano Pharma in a research report on Monday, June 15th. Maxim Group restated a “buy” rating on shares of Zosano Pharma in a research report on Wednesday, May 20th. Finally, Zacks Investment Research raised shares of Zosano Pharma from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $4.00.
The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.93 and a current ratio of 0.93. The stock’s fifty day moving average is $0.86 and its 200 day moving average is $0.85. The stock has a market cap of $54.34 million, a P/E ratio of -0.56 and a beta of 2.71.
Zosano Pharma (NASDAQ:ZSAN) last announced its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.04. Equities research analysts predict that Zosano Pharma Corp will post -0.5 EPS for the current year.
Several large investors have recently made changes to their positions in the stock. Telemetry Investments L.L.C. lifted its stake in Zosano Pharma by 202.7% in the first quarter. Telemetry Investments L.L.C. now owns 2,607,767 shares of the biotechnology company’s stock worth $1,466,000 after purchasing an additional 1,746,267 shares during the last quarter. BlackRock Inc. raised its stake in shares of Zosano Pharma by 6.8% during the first quarter. BlackRock Inc. now owns 385,675 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 24,431 shares in the last quarter. Sabby Management LLC bought a new stake in shares of Zosano Pharma during the first quarter valued at approximately $114,000. Finally, UBS Group AG raised its stake in shares of Zosano Pharma by 45.8% during the first quarter. UBS Group AG now owns 99,932 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 31,375 shares in the last quarter. 17.04% of the stock is owned by hedge funds and other institutional investors.
About Zosano Pharma (NASDAQ:ZSAN)
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.